US 11,999,722 B2
Disubstituted pyrazole compounds
David Andrew Coates, New Palestine, IN (US); Timothy Barrett Durham, Indianapolis, IN (US); Richard Duane Johnston, Greenfield, IN (US); Steven Marc Massey, Indianapolis, IN (US); Patrick Gianpietro Spinazze, Avon, IN (US); Douglas Richard Stack, Fishers, IN (US); and James Lee Toth, Knightstown, IN (US)
Assigned to ELI LILLY AND COMPANY, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Sep. 17, 2021, as Appl. No. 17/478,080.
Application 17/478,080 is a continuation of application No. 16/902,806, filed on Jun. 16, 2020, granted, now 11,124,500.
Claims priority of provisional application 62/975,887, filed on Feb. 13, 2020.
Claims priority of provisional application 62/862,382, filed on Jun. 17, 2019.
Prior Publication US 2022/0017496 A1, Jan. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 403/14 (2006.01); A61P 1/16 (2006.01); A61P 3/10 (2006.01); A61P 9/04 (2006.01); A61P 13/12 (2006.01)
CPC C07D 403/14 (2013.01) [A61P 1/16 (2018.01); A61P 3/10 (2018.01); A61P 9/04 (2018.01); A61P 13/12 (2018.01)] 7 Claims
 
1. A method of treating chronic kidney disease in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula:

OG Complex Work Unit Chemistry
wherein
X is N, or C substituted with CN;
R1 is selected from: H,

OG Complex Work Unit Chemistry
R2 and R3 are both H, or one is H and the other is OH;
R4, R5, R6, R7 and R9 are independently H or CH3;
R8 is H, CH3, CH2CH2OH, C(═O)CH2NH2, or C(═O)CH3; and
R10 is OH or NH2;
or a pharmaceutically acceptable salt thereof.